Publications and Presentations

Filter By:

Binimetinib and Encorafenib

09/09/2017

European Society for Medical Oncology Congress

RESULTS OF COLUMBUS PART 2: A Phase 3 Trial of Encorafenib Plus Binimetinib Versus Encorafenib in BRAF-Mutant Melanoma

R. Dummer, et al.

Binimetinib

09/09/2017

European Society for Medical Oncology Congress

BEACON CRC: Safety Lead-In (SLI) for the Combination of Binimetinib (BINI), Encorafenib (ENCO), and Cetuximab (CTX) in Patients (Pts) with BRAFV600E Metastatic Colorectal Cancer (mCRC)

S. Huijberts, et al.

Binimetinib

06/03/2017

American Society of Clinical Oncology Meeting

Phase 1b/2 Trial of Ribociclib + Binimetinib in Metastatic NRAS-Mutant Melanoma: Safety, Efficacy, and Recommended Phase 2 Dose

Martin Schuler, et al.

Binimetinib and Encorafenib

11/09/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Results of COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

K. T. Flaherty, et al.

Binimetinib

11/07/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Management of MEK inhibitor (MEKi) Toxicities of Binimetinib (BINI) in the NEMO Trial

P. A. Ascierto, et al.

Binimetinib

11/07/2016

2016 Society for Melanoma Research (SMR) Annual Congress

Efficacy of Binimetinib in Patients with NRAS-mutant Melanoma: Subgroup Analysis of the Phase 3 NEMO Study

A. Arance, et al.

ARRY-797

08/31/2016

European Society of Cardiology Congress 2016

Phase 2 Study of A797, an Oral, Selective p38 Mitogen-Activated Protein Kinase Inhibitor, in Patients With Lamin A/C–Related Dilated Cardiomyopathy

C. A. MacRae, et al.

Filanesib

07/19/2016

PubMed.gov

A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.

Chari A., et al.

Encorafenib

07/01/2016

ESMO World Congress of Gastrointestinal Cancer

Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm) Colorectal Cancer: Phase 2 Results

J. Tabernero, et al.

Binimetinib

06/06/2016

American Society of Clinical Oncology Meeting

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma

R. Dummer, et al.